Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease - Wikidata - awgldk - TriplyDB

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

http://www.wikidata.org/entity/Q34247849

about

Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Exercise training increases size of hippocampus and improves memory Unified theory of Alzheimer's disease (UTAD): implications for prevention and curative therapy Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 Role of HIV in amyloid metabolism Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria Testing the right target and right drug at the right stage The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected The development, past achievements, and future directions of brain PET Alliance for aging research AD biomarkers work group: structural MRI.The diagnosis and management of mild cognitive impairment: a clinical review.Genetic risk for Alzheimer's disease alters the five-year trajectory of semantic memory activation in cognitively intact elders Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy The clinical value of large neuroimaging data sets in Alzheimer's disease The Translational Medicine Ontology and Knowledge Base: driving personalized medicine by bridging the gap between bench and bedside Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Cdk5 is a New Rapid Synaptic Homeostasis Regulator Capable of Initiating the Early Alzheimer-Like Pathology.³H-deprenyl and ³H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain Multimodality imaging of Alzheimer disease and other neurodegenerative dementias Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2 Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.Communicating mild cognitive impairment diagnoses with and without amyloid imaging.Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images.Assessment of cognition in mild cognitive impairment: a comparative study Neuroprotective Effects of Physical Activity: Evidence from Human and Animal Studies.An expanded role for neuroimaging in the evaluation of memory impairment.Structural and functional imaging correlates of cognitive and brain reserve hypotheses in healthy and pathological aging.The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.Imaging approaches for dementia.The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging.Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention.

P2860

Q24193707-DEEB8C8F-9A64-489E-8E52-E63460100947 Q24194742-21EC1D24-A46F-4410-9261-5C4BBC707630 Q24619698-93CE96F9-2237-407C-96A4-F15F1A42BF7A Q26382049-2FBA2542-3676-4319-9056-CD2AC923DE33 Q26744105-4A0E5319-F4DA-4755-AEAA-A4F6B80991B5 Q26750249-17DE467E-3468-499F-9870-1C3B95A0CF2E Q26801629-C6FCE977-80F4-4169-A8CD-F75303228415 Q26824179-5B10D221-B341-4812-AD35-28EC1778B55A Q26864063-39B174FE-8874-4FA1-8BFA-933CA958E3CB Q26864854-01355B57-FA63-42C0-81A9-886F0D5F29CC Q27006831-9F0A5BA7-4861-4E80-8A14-D2736C2C31D5 Q27007436-17D796AF-FAF7-405B-A793-D19167C00B8A Q27026331-5EE089A4-3DC2-4783-B08A-E43C172A0C4A Q27692607-E43FBA05-A2EB-49EE-A69A-F32209A25848 Q27693353-F9215E91-17FB-425E-834E-A43857237AFD Q28391284-ADCAC892-5AAE-4F49-BC39-29D306A29D59 Q28488143-D08668AE-C2D5-4037-9C84-B4FFE215FBF7 Q28488690-C539D530-DDC0-4AA4-89F9-00040A21BF4B Q28709465-8439845D-6261-4834-BFC1-E1C5837C0191 Q28744215-E09F8CE9-516A-48CA-967A-164D68265863 Q29620245-C21068B2-48A2-45F7-B38A-95DEC5F01B8C Q30279162-44DB92D1-4A0C-4FBD-BD2D-FFA3FC2D9B78 Q30542245-DBE5F0E2-7BDD-48B6-9BC9-ECB0893D5D30 Q30870819-239EE9D0-5ED5-4FC5-8ADF-CF22481C945F Q30871982-0C5BCF52-F4EC-4CDC-AA28-732F300DE397 Q30971403-D3EBEE02-38C6-4B19-920E-92C396C9B03A Q30981669-DE65F93A-219D-45E9-9B94-7F7C35B715D4 Q33556068-E1CAD7DE-275D-44C2-BA0E-0C52546A5D20 Q33604453-B3BA282F-B7CA-44D8-BB87-5CF989EDC412 Q33640373-6CC9E6FD-7707-4CDE-8557-A3B7583799FA Q33683377-092964A9-8B0C-4B48-8024-9F0B4DBA16DB Q33701135-B8C4AC3A-077C-41D5-9802-90561E774E7B Q33703851-04D3E3B6-9CFE-4C9B-BA50-36DA32318E08 Q33712569-5ADF3E44-A63F-4A61-8E56-BC8A9D186970 Q33830698-A899CF05-4C4E-49C9-A08D-5CC6D4EE4BB5 Q33997384-FFB631B9-10E4-4F88-95DF-6ABB6CCFA60E Q34065449-9BD314BD-4E2F-41BD-8D32-4EB56F73124B Q34089121-B7A04F33-354A-46CC-B215-798DF40C9F13 Q34296479-39EEBE4C-375F-4F6F-93B6-291141239983 Q34303501-B0D451C9-CEFA-46CE-B55A-4D528534AC82

P2860

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

http://www.wikidata.org/entity/Q34247849

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Brain beta-amyloid measures an ...... airment to Alzheimer's disease

@ast

Brain beta-amyloid measures an ...... airment to Alzheimer's disease

@en

Brain beta-amyloid measures an ...... airment to Alzheimer's disease

@nl

type

label

Brain beta-amyloid measures an ...... airment to Alzheimer's disease

@ast

Brain beta-amyloid measures an ...... airment to Alzheimer's disease

@en

Brain beta-amyloid measures an ...... airment to Alzheimer's disease

@nl

prefLabel

Brain beta-amyloid measures an ...... airment to Alzheimer's disease

@ast

Brain beta-amyloid measures an ...... airment to Alzheimer's disease

@en

Brain beta-amyloid measures an ...... airment to Alzheimer's disease

@nl

P1433

Q34247849-5A0277BE-1C79-4FC2-B9D3-DB02FA5DE997

P1476

Q34247849-90BFCC25-F14A-45AC-90F4-65F1D0B567E8

P2093

Q34247849-0F060F7F-8219-4C73-B133-23D33C08B1A5

Q34247849-395B3B23-CE1D-4460-87CF-370041154158

Q34247849-3F60A326-7B95-487B-A8E0-D84942086433

Q34247849-5B8183D3-99E3-4804-A293-FD026E382895

Q34247849-6062CE45-4E2C-46A6-81D6-83442ED4821D

Q34247849-7DBF237F-C6C1-417A-B50A-CF90293DB613

Q34247849-7DBF9AC1-F6BE-4408-8B45-D7C0ACEE19E0

Q34247849-AEB7C197-DEB4-4AED-AEA5-D1886739C14C

P2860

Q34247849-018DD45C-71C5-4CE0-B642-EE4505A216EF

Q34247849-020765E0-3AC2-4784-AEB7-0B6C2D9F6E8E

Q34247849-059CBE67-2BA4-4838-9960-07BA98643989

Q34247849-06FB4174-DEC9-48EE-8AC8-D718C92CD88B

Q34247849-078E09B6-AA80-4F82-970B-FFFE434717A0

Q34247849-08925E29-8677-4F1F-9E93-45C10FC09B4A

Q34247849-08BCB23D-E6F7-4125-9E57-4199D1DFE69B

Q34247849-0A0CE2D9-79D7-4893-B090-15870C96BFF4

Q34247849-0A7D81D0-8739-4D49-A880-C6D2F06664A5

Q34247849-0A8495E9-6676-42FC-9AA3-1D73F0564E6C

P304

Q34247849-AA95A9B5-B4CB-4F37-A75C-92F8C424BA39

P31

Q34247849-865D9C97-0079-44C7-B2C3-65BEFD8505A7

P356

Q34247849-666093B5-3444-4A11-98FF-A0AF44B73D82

P407

Q34247849-232AE2A5-0F03-4456-AC6D-A43250327784

P433

Q34247849-DD9FBB31-9864-44D3-9261-7345A437DACB

P478

Q34247849-2FAB2744-6902-4241-9ED3-FA34DBF2F210

P50

Q34247849-0C03EC25-1068-4E72-A230-C2025F4BDB0B

Q34247849-4830A50F-4320-4796-BD71-994AB27690C6

Q34247849-518B9206-B27D-42B9-85E1-C0AB102B4F84

Q34247849-7A8841BD-782D-4348-AB30-66F0FA350942

Q34247849-9589551A-52C8-4948-BC79-1C9195E7556A

Q34247849-BD516018-2F85-4D02-A895-E41B7A72C297

Q34247849-BDABFC6B-781F-4543-BA6D-BEA6402E7036

Q34247849-E8D6FAA6-3798-491F-AF02-5AA7016ECD9B

P577

Q34247849-9E6C7A3A-36E8-4370-84A1-9AF1D94B0580

P5875

Q34247849-ED3DFE20-2F97-405C-B903-082AF84CCE0C

P698

Q34247849-388A91E6-7096-42FF-B665-6AE23861C410

P921

Q34247849-20EDB509-605B-4A90-AF70-3574B9C95A35

P932

Q34247849-2FC0226B-E8E0-485F-8587-E600C14A52ED

P356

P1433

P1476

Brain beta-amyloid measures an ...... airment to Alzheimer's disease

@en

P2093

Guang Zeng

http://www.w3.org/2001/XMLSchema#string

Heather J Wiste

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Gunter

http://www.w3.org/2001/XMLSchema#string

Leslie M Shaw

http://www.w3.org/2001/XMLSchema#string

Matthew L Senjem

http://www.w3.org/2001/XMLSchema#string

Prashanthi Vemuri

http://www.w3.org/2001/XMLSchema#string

Stephen D Weigand

http://www.w3.org/2001/XMLSchema#string

Vernon S Pankratz

http://www.w3.org/2001/XMLSchema#string

P2860

The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.

Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain

Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies

Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data.

P304

3336-3348

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BRAIN/AWQ277

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

133

http://www.w3.org/2001/XMLSchema#string

P50

Alzheimer's Disease Neuroimaging Initiative

Matt A Bernstein

Ronald C. Petersen

Michael W. Weiner

John Q. Trojanowski

David S Knopman

P577

2010-10-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47384232

http://www.w3.org/2001/XMLSchema#string

P698

20935035

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

2965425

http://www.w3.org/2001/XMLSchema#string